CL2013001643A1 - Composicion farmaceutica que comprende: 1)n-[(2s)-2,3-dihidroxipropil]-3-(2-fluoro-4-iodoanilino)piridin-4-carboxamida y 2a)2-amino-n-[3-[[3-(2-cloro-5-metoxianilin)quinoxalin-2-yl]sulfamoil]fenil]-2-metilpropanamida o 2b) 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7-ona ; su uso para el tratamiento del cancer; un kit - Google Patents

Composicion farmaceutica que comprende: 1)n-[(2s)-2,3-dihidroxipropil]-3-(2-fluoro-4-iodoanilino)piridin-4-carboxamida y 2a)2-amino-n-[3-[[3-(2-cloro-5-metoxianilin)quinoxalin-2-yl]sulfamoil]fenil]-2-metilpropanamida o 2b) 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7-ona ; su uso para el tratamiento del cancer; un kit

Info

Publication number
CL2013001643A1
CL2013001643A1 CL2013001643A CL2013001643A CL2013001643A1 CL 2013001643 A1 CL2013001643 A1 CL 2013001643A1 CL 2013001643 A CL2013001643 A CL 2013001643A CL 2013001643 A CL2013001643 A CL 2013001643A CL 2013001643 A1 CL2013001643 A1 CL 2013001643A1
Authority
CL
Chile
Prior art keywords
amino
methoxyanilin
iodoanilino
methylpropanamide
quinoxalin
Prior art date
Application number
CL2013001643A
Other languages
English (en)
Inventor
Laurent Debussche
Jianguo Ma
Stuart Mcmillan
Janet Anne Meurer Ogden
Loic Vincent
Carlos Garcia-Escheverria
Original Assignee
Sanofi Sa
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, Merck Patent Gmbh filed Critical Sanofi Sa
Publication of CL2013001643A1 publication Critical patent/CL2013001643A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013001643A 2010-12-09 2013-06-07 Composicion farmaceutica que comprende: 1)n-[(2s)-2,3-dihidroxipropil]-3-(2-fluoro-4-iodoanilino)piridin-4-carboxamida y 2a)2-amino-n-[3-[[3-(2-cloro-5-metoxianilin)quinoxalin-2-yl]sulfamoil]fenil]-2-metilpropanamida o 2b) 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7-ona ; su uso para el tratamiento del cancer; un kit CL2013001643A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42146510P 2010-12-09 2010-12-09
US201161436258P 2011-01-26 2011-01-26
US201161467485P 2011-03-25 2011-03-25
FR1159940 2011-11-03

Publications (1)

Publication Number Publication Date
CL2013001643A1 true CL2013001643A1 (es) 2014-03-28

Family

ID=45464841

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001643A CL2013001643A1 (es) 2010-12-09 2013-06-07 Composicion farmaceutica que comprende: 1)n-[(2s)-2,3-dihidroxipropil]-3-(2-fluoro-4-iodoanilino)piridin-4-carboxamida y 2a)2-amino-n-[3-[[3-(2-cloro-5-metoxianilin)quinoxalin-2-yl]sulfamoil]fenil]-2-metilpropanamida o 2b) 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7-ona ; su uso para el tratamiento del cancer; un kit

Country Status (22)

Country Link
US (1) US20140024653A1 (es)
EP (1) EP2648729A1 (es)
JP (1) JP2013544892A (es)
KR (1) KR20140011311A (es)
CN (1) CN103402518A (es)
AR (1) AR084216A1 (es)
AU (1) AU2011338354A1 (es)
BR (1) BR112013014198A2 (es)
CA (1) CA2820748A1 (es)
CL (1) CL2013001643A1 (es)
CR (1) CR20130246A (es)
DO (1) DOP2013000131A (es)
MA (1) MA34815B1 (es)
MX (1) MX2013006319A (es)
NZ (1) NZ611581A (es)
PE (1) PE20140702A1 (es)
RU (1) RU2013131241A (es)
SG (1) SG190368A1 (es)
TW (1) TW201306837A (es)
UY (1) UY33790A (es)
WO (1) WO2012078832A1 (es)
ZA (1) ZA201303687B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515476A (ja) * 2012-04-06 2015-05-28 サノフイ Ｐｉ３ｋ阻害剤及びｍｅｋ阻害剤を使用する癌の治療方法
JP2015536910A (ja) * 2012-10-11 2015-12-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗がん活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体とｍｅｋインヒビターとの組み合わせ
JP2017505321A (ja) 2014-02-07 2017-02-16 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 異常な細胞成長を処置するための方法および組成物
WO2016014390A1 (en) * 2014-07-25 2016-01-28 Merck Patent Gmbh Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
CN111433604B (zh) * 2017-12-22 2023-12-08 瑞士商艾迪安纳股份有限公司 用于确定抗cd26配体的生物活性的定量细胞方法
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2021361138A1 (en) * 2020-10-16 2023-06-08 Memorial Sloan Kettering Cancer Center Induction of ferroptosis for cancer therapy
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Also Published As

Publication number Publication date
AR084216A1 (es) 2013-05-02
JP2013544892A (ja) 2013-12-19
SG190368A1 (en) 2013-06-28
UY33790A (es) 2012-07-31
WO2012078832A1 (en) 2012-06-14
NZ611581A (en) 2015-02-27
EP2648729A1 (en) 2013-10-16
MA34815B1 (fr) 2014-01-02
KR20140011311A (ko) 2014-01-28
TW201306837A (zh) 2013-02-16
CA2820748A1 (en) 2012-06-14
US20140024653A1 (en) 2014-01-23
AU2011338354A1 (en) 2013-06-27
BR112013014198A2 (pt) 2016-09-13
RU2013131241A (ru) 2015-01-20
PE20140702A1 (es) 2014-06-26
DOP2013000131A (es) 2013-11-15
CR20130246A (es) 2013-09-03
ZA201303687B (en) 2014-01-29
CN103402518A (zh) 2013-11-20
MX2013006319A (es) 2013-07-03

Similar Documents

Publication Publication Date Title
CL2013001643A1 (es) Composicion farmaceutica que comprende: 1)n-[(2s)-2,3-dihidroxipropil]-3-(2-fluoro-4-iodoanilino)piridin-4-carboxamida y 2a)2-amino-n-[3-[[3-(2-cloro-5-metoxianilin)quinoxalin-2-yl]sulfamoil]fenil]-2-metilpropanamida o 2b) 2-amino-8-etil-4-metil-6-(1h-pirazol-5-il)pirido[2,3-d]pirimidin-7-ona ; su uso para el tratamiento del cancer; un kit
NI201200072A (es) Métodos y composiciones para tratar cáncer
CL2014000492A1 (es) Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2011002739A1 (es) Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2009000447A1 (es) Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
CL2013001654A1 (es) Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
BR112012020719A2 (pt) formulação herbicida método de tratamento de plantas com herbicida método de aumento da eficácia de uma formulação herbicida, e, uso de uma composição
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
CL2013002971A1 (es) Compuestos derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina-carboxamida, moduladores mglur5; composición farmacéutica que los comprende; proceso de preparación de ellos; y su uso en el tratamiento de esquizofrenia o enfermedades cognitivas.